Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tirzepatide plus Mibavademab in Obesity
NCT06373146Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Apr 2024
- Primary completion
- Dec 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of mibavademab in obesity, sponsored by Eli Lilly and Company. Started Apr 2024; status: completed.
02
Drugs
mibavademab
03
Conditions
obesity
Beyond the preview
Go deeper on NCT06373146.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06373146.